Proxalutamide

1398046-21-3

517.50

10 mM in DMSO

Others

Proxalutamide (GT0918) is a potent androgen receptor (AR) antagonist.
IC50 & Target: Androgen Receptor[1].
In Vitro: In biochemical assay, Proxalutamide (GT0918) more potently inhibits androgen binding with AR's ligand binding domain than Bicalutamide (11.4x) and MDV3100 (3.5x). In both hormone-sensitive (LNCaP) and CRPC (C4-2) cancer cells, Proxalutamide demonstrates stronger potency to block AR function of gene transcription than Bicalutamide (ca.5-10) and MDV3100 (2-5x) while maintaining full antagonism in CRPC cells. Proxalutamide impairs androgen stimulates AR translocation to cell nuclei hence blocks its binding DNA and shuts down the downstream oncogenic signaling. Moreover, Proxalutamide induces AR down regulation in prostate cancer cells. Proxalutamide not only inhibits proliferation of hormone-sensitive CaP cells, but also more potently inhibits proliferation of CRPC cells. In addition, Proxalutamide inhibits the growth of AR positive breast cancer cells. In contrast, Proxalutamide has minimum effects on the growth of AR-negative CaP cells (PC-3 and DU145), indicating it is a selective AR pathway inhibitor.
In Vivo: The major pharmacokinetic parameters and statistical moment parameters are summarized. The tmax for the pHM-SD and conventional tablets are 0.9+/-0.4 h and 2.5+/-1.1 h, respectively, meaning that the pHM-SD tablets dissolve more quickly than the conventional tablets. Moreover, the difference between the tmax of the two treatments is statistically significant (p<0.05). The mean Cmaxand the AUC0-36 are 5.1+/-2.4 ug/mL and 38.3+/-8.2 ugh/mL for the pHM-SD tablets versus 3.1+/-1.5 ug/mL and 42.1+/-22.3 ugh/mL for conventional tablets, respectively. The relative bioavailability (frel) of the pHM-SD tablets is 125.6% of that for the conventional tablets on average, revealing that the bioavailability of the former is higher. The mean Proxalutamide (GT0918) half-life estimate from the pHM-SD tablets (7.9+/-2.2 h) was similar to that of the conventional tablets (8.4+/-0.5 h), remaining consistent with the following pharmacoki-netic theory: the extent and rate of absorption should not affect elimination.